A MULTICENTER, OPEN-LABEL, PHASE 2 BASKET STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK¿2140 AS A MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH AGGRESSIVE AND INDOLENT B-CELL MALIGNANCIES
- Registry ID
- MK-2140-006
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2023-08-22
- Last update
- 2022-05-20
Conditions
Related clinical trials
- A PHASE I TRIAL OF CLIC-2201 FOR THE TREATMENT OF RELAPSED/REFRACTORY B CELL
MALIGNANCIES
- A MODULAR PHASE I/II OPEN-LABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO
EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF
AZD5492, A T CELL-ENGAGING ANTIBODY TARGETING CD20 IN SUBJECTS WITH RELAPSED
OR REFRACTORY B-CELL MALIGNANCIES (TITANIUM)
- FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF THE BTK DEGRADER, ABBV-101, IN PARTICIPANTS WITH B-CELL MALIGNANCIES
- A FIRST-IN-HUMAN MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ABBV-319 IN B-CELL MALIGNANCIES
- A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND -EXPANSION STUDY OF THE BRUTON TYROSINE KINASE TARGETED PROTEIN DEGRADER BGB-16673 IN PATIENTS WITH B-CELL MALIGNANCIES
- A PHASE 1/2 DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY AND EFFICACY OF ALLOGENEIC CRISPR-CAS9-ENGINEERED T CELLS (CTX110) IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES
View on source registry